SCHEMBL6764459

SCHEMBL6764459

PO/N=C(/Oc1ccccc1)N1CCC2(CC1)OCCO2

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.46
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
MAPK1 P28482 1/20 0.43
CASP1 P29466 1/20 0.43
CASP7 P55210 1/20 0.43
HSD17B10 Q99714 1/20 0.43
TSHR P16473 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 2/20 0.41
KDM4E B2RXH2 2/20 0.38
LMNA P02545 1/20 0.38
NAMPT P43490 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10308052 0.90 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13781697 0.84 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL17655302 0.82 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL12769030 0.82 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL614078 0.77 CYP3A4 (0.59) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2077811 0.66 POLB (0.67) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL13780735 0.66 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL31640697 0.66 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL14117664 0.64 LTA4H (0.55) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A
SCHEMBL2081641 0.63 MEN1 (0.66) ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178560-B2 Therapeutic agents useful for treating pain PURDUE PHARMA L.P. (US) 2012-05-15 US disclosed
US-20100331369-A1 Therapeutic Agents Useful for Treating Pain PURDUE PHARMA L.P. (US) 2010-12-30 US disclosed
US-7776861-B2 Cycloheteroalkenyl compounds used as analgesics and for treating incontinence, inflammatory bowel disease, Parkinson's disease, amyotrophic lateral sclerosis, dementia, epilepsy, retinopathy, pruritus, psychoses, Huntington's disease, headaches, vomiting, dyskinesia or as anxiolytics and antidepressants PURDUE PHARMA L.P. (US) 2010-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331369-A1 Therapeutic Agents Useful for Treating Pain GRIN1, GRIK1, GRIN2B ALDH1A1 1552/4885SMN1; SMN2 25/4885NPC1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.